Table 1. mtDNAcn in peripheral blood leukocytes by selected characteristics of the study patients with localized prostate cancer.

Characteristicsa	Total (N = 1,751)	mtDNAcnb	P valuec
Age at diagnosis, years
<55	339 (19.4)	0.87 (0.37)
55–65	836 (47.7)	0.81 (0.36)
>65	576 (32.9)	0.75 (0.33)	<0.001
BMI at diagnosis, kg/m2
<25	256 (17.6)	0.79 (0.33)
25–29.99 (overweight)	674 (46.3)	0.81 (0.36)
≥30 (obese)	527 (36.2)	0.76 (0.30)	0.04
Smoking status at diagnosis
Non-smoker	819 (47.0)	0.80 (0.35)
Former smoker	782 (44.9)	0.81 (0.35)
Current smoker	140 (8.0)	0.82 (0.38)	0.74
D'Amico risk group
Low	589 (33.6)	0.83 (0.38)
Intermediate	830 (47.4)	0.81 (0.34)
High	332 (19.0)	0.74 (0.31)	<0.001
Total Gleason score
≤6	647 (37.0)	0.83 (0.37)
7	881 (50.3)	0.80 (0.34)
≥8	222 (12.7)	0.74 (0.31)	0.009
Clinical tumor stage
T1	1,095 (62.5)	0.82 (0.36)
T2	569 (32.5)	0.79 (0.35)
T3–T4	74 (4.2)	0.74 (0.25)	0.08
PSA at diagnosis
<10 ng/ml	1,527 (87.4)	0.81 (0.36)
10–20 ng/ml	154 (8.8)	0.77 (0.29)
>20 ng/ml	67 (3.8)	0.75 (0.31)	0.21
Initial primary treatment
Radical prostatectomy	906 (51.7)	0.82 (0.36)
Radiotherapy	376 (21.5)	0.79 (0.34)
Surveillance or unknownd	427 (24.4)	0.80 (0.36)
Other treatmente	42 (2.4)	0.80 (0.36)	0.55

^aReported as count (percentage)

^bReported as mean (standard deviation)

^cFor the differences in mtDNAcn by selected characteristics using ANOVA

^dPatients undergoing active surveillance/watchful waiting or whose initial treatment information was unavailable

^eChemotherapy, cryoablation, high-intensity focused ultrasound, or transurethral resection of prostate

Abbreviations: mtDNAcn, mitochondrial DNA copy number; BMI, body mass index; PSA, prostate-specific antigen.